A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.

The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...

The newly combined company will focus on moving Kadimastem's AstroRx, NLS's DOXA platform, and other therapies through ...

Trace Neuroscience has launched in the U.S. with over $100 million in financing and a goal to develop its UNC13A-targeted ...

Columnist Kristin Neva sometimes get overwhelmed by her increasing caregiver responsibilities, but it helps her to know she's not alone.

Mitochondrial genome mutations may be linked to ALS, per a study, opening the door for new ways to diagnosing and treating ...